Moderna (MRNA) Preferred Stock Liabilities (2017)

Moderna's (MRNA) quarterly Preferred Stock Liabilities came in at $1.2 billion in Q4 2017.

Moderna (MRNA) Preferred Stock Liabilities (2017) Analysis & Trends

Moderna (MRNA) has 1 years of Preferred Stock Liabilities data on file, last reported at $1.2 billion in Q4 2017.

On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $1.2 billion in Q4 2017; TTM through Dec 2017 was $1.2 billion, a N/A change from a year earlier, with the FY2017 full-year figure at $1.2 billion, changed 0.0% from the prior year.
Preferred Stock Liabilities for Q4 2017 stood at $1.2 billion.
Over the last five years, Preferred Stock Liabilities for MRNA reached as high as $1.2 billion in Q4 2017 and fell as low as $1.2 billion in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Moderna	22.52 Bn	17.32 Bn	-566.00 Mn	-

Download Data

Date	Value
Dec 31, 2017	1.18 Bn